Cover Image
Market Research Report

Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases

Published by Frost & Sullivan Product code 910112
Published Content info 110 Pages
Delivery time: 1-2 business days
Price
Back to Top
Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
Published: August 23, 2019 Content info: 110 Pages
Description

Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions

At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.

At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.

The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.

Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).

Factors Contributing to Neurodegenerative Diseases

The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.

Molecular Mechanisms Underlying Neurodegeneration

Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.

Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.

  • Some Multifactorial Conditions to Watch
  • Abnormal protein dynamics
  • Defective protein degradation and aggregation
  • Oxidative stress
  • Free radical formation
  • Impaired bioenergetics
  • Mitochondrial dysfunction
  • Exposure to toxic metals and pesticides
  • Others
  • Coverage of Neurodegenerative Diseases Technologies

This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases', focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.

The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness

The study covers the following topics:

  • Technology roadmap, trends, capabilities, and applications targeted
  • Stakeholder activities, influence, industry initiatives, investment environment, and funding support
  • Regional and global regulation landscape and standardization approaches for tackling challenges
  • Technology benchmarking for smart decisions

An appendix is included, comprising lists of major industry influencers found in the field.

Table of Contents
Product Code: D8BB

Table of Contents

1.0. Executive Summary

  • 1.1. Facts and Findings: Neurodegenerative Diseases
  • 1.2. Research Focus: Neurodegenerative Diseases
  • 1.3. Research Scope: Foreseeing Challenges and Solutions
  • 1.4. Analysis Framework: Frost & Sullivan's Core Value
  • 1.5. Research Methodology

2.0. Technology Landscape and Trends

  • 2.1. Neurodegenerative Diseases: Facts and Challenges
  • 2.2. Neurodegenerative Diseases: Multifactorial Onset
  • 2.3. Neurodegenerative Diseases: Concurrent Triggering Factors
  • 2.4. Neurodegenerative Diseases: Emerging Therapies
  • 2.5. Neurodegenerative Diseases: Complementary Therapies

3.0. Emerging Therapies to Address Neurodegeneration

  • 3.1. Therapeutic and Diagnostic Solutions: PROTACs
  • 3.2. Neurodegenerative Therapies: Targeting Protein Ligands
  • 3.3. Therapeutic and Diagnostic Solutions: Peptoids
  • 3.4. Neurodegenerative Therapies: Five Peptoid Approaches
  • 3.5. Neurodegenerative Therapies: Aggregation Inhibitors
  • 3.6. Neurodegenerative Therapies: Cell Signaling Modulators
  • 3.7. Neurodegenerative Therapies: Biomimetic Neuroprotectors
  • 3.8. Neurodegenerative Therapies: Inflammation Regulators
  • 3.9. Neurodegenerative Therapies: Imaging Diagnostics Biomarkers
  • 3.10. Neurodegenerative Therapies: Summary of Peptoid Interventions
  • 3.11. Therapeutic and Diagnostic Solutions: Stem Cell/Gene Therapies
  • 3.12. Neurodegenerative Therapies: Cell Therapy Developments
  • 3.13. Therapeutic and Diagnostic Solutions: Gut Microbiome
  • 3.14. Neurodegenerative Therapies: Gut Microbiome Interventions
  • 3.15. Therapeutic and Diagnostic Solutions: Nanotech, Prodrug, and Codrug
  • 3.16. Therapeutic and Diagnostic Solutions: Cannabidiols
  • 3.17. Neurodegenerative Therapies: Prevention and Management

4.0. Technology Status Review and Assessment

  • 4.1. Neurodegenerative Preclinical Models: Needs and Complexities
  • 4.2. Neurodegenerative Models' Pitfalls: Alzheimer's Disease
  • 4.3. Neurodegenerative Models' Pitfalls: Parkinson's Disease
  • 4.4. Present Status of Therapeutics Technology
  • 4.5. Alzheimer's Disease Drug Development Status
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.6. Parkinson's Disease Drug Development Status

5.0. Technology Radar Intelligent Solutions

  • 5.1. From Palliative Treatment to Future Strategies
  • 5.2. New Treatment Strategies and Preliminary Outcomes
  • 5.2. New Treatment Strategies and Preliminary Outcomes (continued)
  • 5.3. Monoclonal Antibodies Advancing Clinical Trials
  • 5.4. Pharmacological Agents Enhancing Autophagy
  • 5.5. Top Promising Candidates for Alzheimer's Disease
  • 5.6. Parkinson's Disease Top Companies

6.0. Market Potential and Technology Adoption

  • 6.1. Neurodegenerative Diseases Market Potential
  • 6.2. Overall Environmental Impact Factors
  • 6.3. Best-fit Industry Partnerships: SWOT Analysis
  • 6.4. Collaborative Framework for Neurodegenerative Diseases
  • 6.5. Overview of Business Partnerships and Technology Capabilities
  • 6.6. Key Aspects to Target through Collaborative Initiatives

7.0. Business Landscape and Intellectual Property Analysis

  • 7.1. Actionable Impact on Business Development
  • 7.2. Repercussions on Businesses and Processes
  • 7.3. Technology Transfer Assessment

8.0. Appendix

  • 8.1. Alzheimer's Disease Drug Pipeline
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.2. Parkinson's Disease Drug Pipeline
  • 8.2. Parkinson's Disease Drug Pipeline (continued)

9.0. Key Industry Contacts

  • 9.1. Key Industry Influencers
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • Legal Disclaimer
Back to Top